Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097157431> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2097157431 endingPage "700" @default.
- W2097157431 startingPage "697" @default.
- W2097157431 abstract "The use of doxorubicin has shown some activity in malignant mesothelioma but prolonged administration is hampered by cardiotoxicity. Caelyx, a new liposomal and pegylated form of doxorubicin has shown a better pharmacokinetic and toxic profile then doxorubicin. In a phase II study, the efficacy and toxicity of Caelyx was tested in previously untreated patients with malignant pleural mesothelioma.Thirty-three patients who had measurable or evaluable histologically confirmed malignant pleural mesothelioma were included in the study. Caelyx (45 mg/m2) was given i.v. on outpatient base every four weeks for nine cycles or till progression or unacceptable toxicity occurred.Of the 33 patients, 32 were evaluable for toxicity and 31 for response. Two patients had a partial response (6%, 95% confidence interval: 0.2%-20.2%). The median survival was 13 months. Forty percent of the patients received >6 cycles. Toxicity was mild with palmar plantar erythrodysesthesia being most pronounced (62% grade 1-2, 6% grade 3) and of limited duration. Ten percent of patients had grade 3 anemia and 3% grade 3 thrombocytopenia. Two patients (6%) had grade 3 or 4 cardiac toxicity, which was not drug related.At the prescribed dose, single agent Caelyx is well tolerated but its activity in chemotherapy-naive mesothelioma patients does not warrant further investigation as a single agent." @default.
- W2097157431 created "2016-06-24" @default.
- W2097157431 creator A5003892829 @default.
- W2097157431 creator A5017960622 @default.
- W2097157431 creator A5022063365 @default.
- W2097157431 creator A5031620636 @default.
- W2097157431 creator A5049408454 @default.
- W2097157431 creator A5049735686 @default.
- W2097157431 creator A5067989340 @default.
- W2097157431 date "2000-06-01" @default.
- W2097157431 modified "2023-10-11" @default.
- W2097157431 title "Caelyx™ in malignant mesothelioma: A phase II EORTC study" @default.
- W2097157431 cites W1769308960 @default.
- W2097157431 cites W1846163577 @default.
- W2097157431 cites W1999393813 @default.
- W2097157431 cites W2028701020 @default.
- W2097157431 cites W2037466909 @default.
- W2097157431 cites W2050014528 @default.
- W2097157431 cites W2113992326 @default.
- W2097157431 cites W2122514344 @default.
- W2097157431 cites W2125980018 @default.
- W2097157431 cites W2160684474 @default.
- W2097157431 cites W2171548026 @default.
- W2097157431 cites W2172010513 @default.
- W2097157431 cites W3148471154 @default.
- W2097157431 cites W4298031624 @default.
- W2097157431 doi "https://doi.org/10.1023/a:1008346925273" @default.
- W2097157431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10942058" @default.
- W2097157431 hasPublicationYear "2000" @default.
- W2097157431 type Work @default.
- W2097157431 sameAs 2097157431 @default.
- W2097157431 citedByCount "50" @default.
- W2097157431 countsByYear W20971574312012 @default.
- W2097157431 countsByYear W20971574312014 @default.
- W2097157431 countsByYear W20971574312017 @default.
- W2097157431 crossrefType "journal-article" @default.
- W2097157431 hasAuthorship W2097157431A5003892829 @default.
- W2097157431 hasAuthorship W2097157431A5017960622 @default.
- W2097157431 hasAuthorship W2097157431A5022063365 @default.
- W2097157431 hasAuthorship W2097157431A5031620636 @default.
- W2097157431 hasAuthorship W2097157431A5049408454 @default.
- W2097157431 hasAuthorship W2097157431A5049735686 @default.
- W2097157431 hasAuthorship W2097157431A5067989340 @default.
- W2097157431 hasBestOaLocation W20971574311 @default.
- W2097157431 hasConcept C126322002 @default.
- W2097157431 hasConcept C141071460 @default.
- W2097157431 hasConcept C142724271 @default.
- W2097157431 hasConcept C143998085 @default.
- W2097157431 hasConcept C2776694085 @default.
- W2097157431 hasConcept C2777407522 @default.
- W2097157431 hasConcept C2778233292 @default.
- W2097157431 hasConcept C2781303535 @default.
- W2097157431 hasConcept C29730261 @default.
- W2097157431 hasConcept C31760486 @default.
- W2097157431 hasConcept C71924100 @default.
- W2097157431 hasConcept C90924648 @default.
- W2097157431 hasConceptScore W2097157431C126322002 @default.
- W2097157431 hasConceptScore W2097157431C141071460 @default.
- W2097157431 hasConceptScore W2097157431C142724271 @default.
- W2097157431 hasConceptScore W2097157431C143998085 @default.
- W2097157431 hasConceptScore W2097157431C2776694085 @default.
- W2097157431 hasConceptScore W2097157431C2777407522 @default.
- W2097157431 hasConceptScore W2097157431C2778233292 @default.
- W2097157431 hasConceptScore W2097157431C2781303535 @default.
- W2097157431 hasConceptScore W2097157431C29730261 @default.
- W2097157431 hasConceptScore W2097157431C31760486 @default.
- W2097157431 hasConceptScore W2097157431C71924100 @default.
- W2097157431 hasConceptScore W2097157431C90924648 @default.
- W2097157431 hasIssue "6" @default.
- W2097157431 hasLocation W20971574311 @default.
- W2097157431 hasLocation W20971574312 @default.
- W2097157431 hasOpenAccess W2097157431 @default.
- W2097157431 hasPrimaryLocation W20971574311 @default.
- W2097157431 hasRelatedWork W2056299406 @default.
- W2097157431 hasRelatedWork W2094475704 @default.
- W2097157431 hasRelatedWork W2143449387 @default.
- W2097157431 hasRelatedWork W2738785033 @default.
- W2097157431 hasRelatedWork W3011400996 @default.
- W2097157431 hasRelatedWork W3030216814 @default.
- W2097157431 hasRelatedWork W4323666172 @default.
- W2097157431 hasRelatedWork W4362704286 @default.
- W2097157431 hasRelatedWork W4385199638 @default.
- W2097157431 hasRelatedWork W60351979 @default.
- W2097157431 hasVolume "11" @default.
- W2097157431 isParatext "false" @default.
- W2097157431 isRetracted "false" @default.
- W2097157431 magId "2097157431" @default.
- W2097157431 workType "article" @default.